Pancreatic Cancer: 2018 Highlights And Looking Forward to 2019
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Due to numerous factors, including rising rates of obesity and smoking, for example, pancreatic cancer jumped to number three, and…
Molecular Profiling: Getting to Know Your Tumor
Dr. Johanna Bendell explains the value of molecular profiling. It can indicate which type of chemotherapy will be more successful on your tumor.
BRCA’s Role in Pancreatic Cancer Investigated
The relationship between BRCA and pancreatic cancer, and how that affects treatment, is the focus of clinical trials looking at PARP inhibitors.
Exploring the Effectiveness of an Experimental Class of Drug
Does adding a PARP inhibitor drug to standard treatment help control the spread of advanced pancreatic cancer in patients with the BRCA mutation?
The Impact of BRCA Is Broader Than Breast and Ovarian Cancer
Rona Greenberg discusses the impact of BRCA2 on her family, and her search for the best clinical trial for her needs after her pancreatic cancer diagnosis.
